TFA Therapeutics, Inc. (RAJAF) stock
RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$9.18+0.00 (0.00%)
Close on Oct 16, 2026Market cap –P/E –Yield –
TFA Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
TFA Therapeutics's gross margin for the twelve months ending Dec 31, 2023 was 86.8%. For fiscal 2025 it was 61.1%, against 72.3% the year before. The highest annual figure on record is 86.8% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.1% | −11.2 |
| FY2024 | Dec 31, 2024 | 72.3% | −14.5 |
| FY2023 | Dec 31, 2023 | 86.8% | +12.6 |
| FY2022 | Dec 31, 2022 | 74.2% | +94.3 |
| FY2021 | Dec 31, 2021 | -20.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | 90.2% | – |
See a number that looks wrong?